THE
WOMEN AND HEART DISEASE AWARENESS CAMPAIGN:
Awareness
+ Fear + Drugs
Heart
disease is the number one killer of women.
½
million women in the U.S. die each year of cardiovascular
disease—higher than the number of men and the next seven
causes of death in women.
An
American woman dies every two minutes of heart disease.
They're
scaring us with statistics again. These statistics were
quoted recently in the media because February was American
Heart Month aimed at increasing women's awareness of their
risk of developing heart disease. The campaign was launched
by First Lady Laura Bush who encouraged women to wear a
red dress on February 6 while the fashion industry announced
that it would send a traveling fashion show with models
wearing red dresses to five major cities—all in the cause
of giving “women a personal and urgent wake-up call about
their risk for heart disease.”
Apparently,
women are woefully unaware of heart disease. A survey cited
by the campaign found that only 9% of women, aged 45 to
64 years, named heart disease as the condition they most
fear, while 61% named breast cancer. In a major effort to
raise the fear level, the heart disease awareness campaign
is following the path of the breast cancer awareness campaign,
which in its early days told women that one
in eight would get breast cancer. This
statistic successfully raised fears, especially when no
one explained that breast cancer is overwhelmingly a disease
of older women and that one in eight women get breast cancer
only if they live to be 90. Breast cancer is
the leading cause of death for women, aged 40-44 years.
As intended, this particular statistic got
many women in their 40s to make a mammography appointment.
It seemed to be in no one's interest to explain that women
in this age group do not have a high rate of death from
anything.
Here
we go again. Yet another disease awareness campaign, complete
with its own pin—a tiny red dress. The first thing to be
skeptical about in any disease awareness campaign are the
statistics showing how widespread the problem is. Yes, heart
disease is the number one killer of women, but the critical
issue is the number of women who die prematurely
of heart disease. Taken from that perspective, heart-related
annual deaths drop from the above-quoted ½ million
to 50,000 women under the age of 65 years. Or put another
way, nearly 80% of the heart-related deaths in women occur
over the age of 75.
After
age 50, women begin to develop and die of heart disease
at a rate equal to that of men. This statistic
is only somewhat accurate because it fails to convey the
fact that women are a good 15 years older by the time equality
kicks in. No doubt, women in early middle age would not
be scared enough if they were told that the average age
for a first heart attack is about 70 years .
The
next thing to be skeptical about in any disease awareness
campaign is the sponsor. Ask yourself who profits from raising
fear of a particular disease—and then follow the money.
American Heart Month was sponsored by two government agencies:
the National Heart, Lung and Blood Institute (NHLBI) and
the National Institutes of Health. That's what the Web site
says. But who funds the campaign? You'll find the answer
on the NHLBI Web site, which lists another sponsoring organization
called WomenHeart: National Coalition for Women with Heart
Disease. The corporate funders of this group include PHARMA,
the trade association for the pharmaceutical industry, and
ten companies that make heart drugs or devices. (Breast
Cancer Awareness Month is funded by AstraZeneca, makers
of the world's best-selling anti-breast cancer drug, tamoxifen.)
One
might ask what could be possibly be the downside of a campaign
that encourages healthy symptom-free women between the ages
of 40 and 60 years to ask their doctors about their personal
risk factors for heart disease. Here's one: It is in the
pharmaceutical industry's interest to make women and doctors
think that heart disease occurs right after menopause when
estrogen levels decline—that's a big reason why estrogen
“replacement” therapy became so widely prescribed to women
in early middle age as a heart disease preventive.
Now
the pharmaceutical industry needs another drug that healthy
women can take for the rest of their lives, and there are
plenty of choices, ranging from aspirin to cholesterol-lowering
drugs. Women are underrepresented in the statin and aspirin
clinical trials, making up less than one-third of all participants.
This leaves a crucial unanswered question: Do the benefits
outweigh the risks of these drugs for healthy but high-risk
women?
Increased
awareness of any disease inevitably results in drawing broad
boundaries around who is at high risk. Heart disease awareness
is likely to funnel healthy women to inappropriate and inaccurate
testing that, in turn, will lead to inappropriate lifelong
drug therapy. That's why you see so many drug company-sponsored
ads that do not mention a drug but simply tell consumers
to ask their doctors about having a cholesterol-screening
test or a bone-density test.
What's
more, the standard non-pharmacologic recommendations to
high-risk women are already well known: lose excess weight;
get blood pressure* under control; exercise regularly; stop
smoking; etc. Following these recommendations “will reduce
the risk of heart disease as well as the risk of diabetes
which is also a risk for heart disease,” said Judith Walsh,
MD, associate professor of clinical medicine at the Women's
Health Clinic Research Center, University of California
at San Francisco, in a telephone interview. “The heart disease
awareness campaign should focus women on a healthy lifestyle,”
she said.
Asked
about the likely possibility that doctors may instead focus
on cholesterol testing, Dr. Walsh responded, “The issue
with cholesterol is that it is a number that needs to be
interpreted within the context of other heart disease risk
factors. If a woman is young and otherwise healthy and has
a high cholesterol, her overall risk for heart disease is
still very very low,” she said, “but as a woman gets older—reaching
her 70s—and has high blood pressure and diabetes and then
has high cholesterol—that's different.”
A
pharmaceutical industry-fueled awareness campaign is not
likely to give more than lip service to lifestyle changes;
nor will it look at factors outside the medical care system's
purview. Arguably, poverty is an important risk for premature
deaths from heart disease, one that goes unmentioned in
the awareness campaign. Conversely, low rates of heart disease
are associated with white women and women of affluence.
A traveling fashion show might very well be targeting the
wrong group of women.
*A
Cochrane review of all trials in which women with hypertension
had been randomly assigned to a drug or a placebo came to
this conclusion: drug treatment for white women with high
blood pressure between the ages of 30 and 54 years provides
no benefit or harm.
Maryann
Napoli, March 2004